Abortion Pill Ban Sweeps Nation, Cutting Off Millions

The Fifth Circuit Court of Appeals has stopped nationwide access to mifepristone by mail and telehealth, requiring the abortion pill to be dispensed in person. This ruling is effective immediately and may soon be considered by the Supreme Court.

Background of the Ruling

A three-judge panel unanimously sided with Louisiana, which sued the FDA to reverse a rule allowing mifepristone to be prescribed through telehealth. The decision claims that the FDA's loosened regulations led to harm, despite decades of safety reviews.

Impact on Abortion Access

Mifepristone is part of a two-drug regimen for medication abortion, and this ruling affects access profoundly. Medication abortions account for about two-thirds of all abortions in the U.S., with many previously conducted via telehealth in states with strict abortion laws.

The decision particularly affects marginalized communities that relied on telehealth for more accessible reproductive care, making abortions costlier and less accessible.

Reactions and Next Steps

Reproductive rights groups have criticized the decision as not based on science or patient safety. They argue that it targets effective means of accessing care across state lines.

The case is moving to the Supreme Court. Louisiana now acts as plaintiff, backed by concerns over Medicaid costs and existing state abortion bans, altering the standing question.

Until further notice, women must obtain mifepristone in person, as telehealth prescriptions are suspended federally, impacting even states with shield laws.